-88%

Population-based cancer survival in the Golestan province in the northeastern part of Iran 2007–2012

Original price was: $24.59.Current price is: $2.99.

Title: Population-based cancer survival in the Golestan province in the northeastern part of Iran 2007–2012
Author: Saeed Nemati a, Elnaz Saeedi a, Gholamreza Roshandel b, Azin Nahvijou a, Abbas Badakhshan c,Mahnaz Akbari d, Seyed Mehdi Sedaghat c, Susan Hasanpour-Heidari b, Reza Hosseinpour b,Faezeh Salamat c, Fereshteh Lotfi a, Ardeshir Khosravi e, Isabelle Soerjomataram f, Freddie Bray f,Kazem Zendehdel a,*
Publication: Cancer Epidemiology
Publisher: Elsevier Inc
Year: 2022
Language: English
Pages: 5
Format: PDF
File size:1,710 KB
DOI: 10.1016/j.canep.2021.102089
CBID: CBR272

Categories: Researches, Medical Researches Tags: Cancer; Cancer control program; Population-based cancer registries; Population-based survival., Medical Researches

Description
Reviews (0)

Abstract

Objective

We studied 5-year relative survival (RS) for 14 leading cancer sites in the population-based cancer registry (PBCR) of Golestan province in the northeastern part of Iran.

Methodology

We followed patients diagnosed in 2007–2012 through data linkage with different databases, including the national causes of death registry and vital statistics office. We also followed the remaining patients through active contact. We used relative survival (RS) analysis to estimate 5-year age-standardized net survival for each cancer site. Multiple Imputation (MI) method was performed to obtain vital status for loss to follow-up (LTFU) cases.

Results

We followed 6910 cancer patients from Golestan PBCR. However, 2162 patients were loss to follow-up. We found a higher RS in women (29.5%, 95% CI, 27.5, 31.7) than men (21.0%, 95% CI, 19.5, 22.5). The highest RS was observed for breast cancer in women (RS=49.8%, 95% CI, 42.2, 56.9) and colon cancer in men (RS=37.9%, 95% CI, 31.2, 44.6). Pancreatic cancer had the lowest RS both in men (RS= 8.7%, 95% CI, 4.1, 13.5) and women (RS= 7.9%, 95% CI, 5.0, 10.8)

Conclusion

Although the 5-year cancer survival rates were relatively low in the Golestan province, there were distinct variations by cancer site. Further studies are required to evaluate the survival trends in Golestan province over time and compare them with the rates in the neighboring provinces and other countries in the region.

Graphical Abstract

Population-based cancer survival in the Golestan province in the northeastern part of Iran 2007–2012 6

Highlights

• This study is one of the most comprehensive attempts to estimate population-based cancer survival in the EMRO Region.
• Cancer survival in Golestan province was pretty low.
• The overall 5-year net survival was 25% in Golestan province.
• The highest 5-year net survival was in breast, colon, melanoma, leukemia, and rectum cancers.

1 Introduction

Population-based cancer survival is a key metric to evaluate the effectiveness of cancer care within a cancer control program . It uses data from the population-based cancer registry (PBCR) and provides evidence for patient outcomes at the general population level . Such data are also valuable for comparing the relative effectiveness of cancer control activities within or between countries based on well-designed protocols, data collection, and robust statistical methods .

The Golestan PBCR was established in 2001, and the first report on cancer incidence was published in 2006. Several global attempts like CONCORD or SurvCan study have investigated population-based survival of cancer . However, the data from Middle East countries and Iran are limited. Except for the reports provided in the CONCORD-3 study for esophageal and stomach cancer, population-based survival proportions from Iran have not yet been reported. Therefore, we attempted to present 5-year relative survival among men and women using data from the Golestan PBCR for 14 leading cancer sites.